Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

By D. Khoury, D. Cromer, A. Reynaldi, T. Schlub, A. Wheatley, J. Juno, K. Subbarao, S. Kent, J. Triccas, M. Davenport. Nature Medicine, 2021

3,622 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

mRNA Vaccines in the COVID-19 Pandemic and Beyond. (2021, background): “30, 2021, a preponderance of evidence suggests that total S-specific immunoglobulin G (IgG), RBD-specific IgG, and SARS-CoV-2 neutralizing antibodies are effective correlates of protection for all COVID-19 vaccines, including those using mRNA (46, 47).”
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2021, positive): “However, while neutralization of wild-type SARS-CoV-2 has been shown to predict the effectiveness of vaccines against variants (Earle et al., 2021; Khoury et al., 2021), it is unclear whether this correlation will be maintained among boosted individuals and for highly mutated variants like Omicron (”
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review (2021, positive): “However, one study based on seven vaccines reported a high correlation between neutralization titres and protection estimated in phase III trials [155].”